Bristol's Oncology Strategy: Cover All The Bases To Keep The Lead
Bristol stresses comprehensive approach to lung cancer – its top priority – with trials from early to late stages, a thoughtful biomarker development program and a pipeline stocked with drugs that have a wide range of targets.
You may also be interested in...
With Opdivo sales up to $840m in the second quarter, Bristol execs once again make the case for trial strategy in the all-important first-line lung cancer indication and say they look forward to the CheckMate 026 data “in weeks not months.”
GSK, Bayer, Celgene, Amgen, AstraZeneca, Bristol-Myers Squibb, Sanofi, Merck & Co and AbbVie are among the pharma companies due to report second-quarter results imminently. As the financial reporting season moves into a second week, Scrip takes a look at the key things to watch for.
Merck’s Keytruda improved progression-free survival and overall survival in previously untreated non-small cell lung cancer patients in the highly-anticipated KEYNOTE-024 trial, all but guaranteeing a rapid FDA approval in the indication.